Ruxolitinib 1.5% cream significantly reduces pruritus and lesion severity among adults with prurigo nodularis for up to 12 weeks of treatment.

The primary endpoint was at least a four-point improvement from baseline in the Worst Itch Numeric Rating Scale (WI-NRS4 ... a ≥ 4-point improvement in WI-NRS at week 12 vs 20.6% of the vehicle ...

Faster and deeper itch relief than anti-IL-4/13 agents4 ... 1 NRS-4: a peak pruritus numeric rating scale (PP-NRS) weekly mean score with a ≥4-point reduction from baseline 2 EASI-75 ...

Combining Deep Pruritus Relief, Effective Skin Clearance, and a Well-tolerated Safety ProfileHONG KONG, Apr 9, 2025 - (ACN Newswire) - SinoMab BioScience ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Efficacy was measured by a health care provider rating a person’s rash and itching using different scales (see table ... and a PP-NRS score of at least 4. Most people included in the studies ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30. Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.

The Pruritus NRS measures how bad your itching is using a scale of 0 (no itch) to 10 (worst itch). In both ADvocate trials, a significantly larger percentage of people had an IGA response in the ...